Current research projects
Clinical Trials
Glomerulopathies
- Phase 3, multicentre, randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of sibeprenlimab administered subcutaneously in subjects with immunoglobulin A nephropathy
- Metformin versus Tolvaptan in adults with Autosomal Dominant Plycystic Kidney Disease: a phase 3a, indipendent, multi-centre, 2 parallel arms randomized-controlled trial
- Sperimentazione di fase 3, multicentrica, randomizzata, in doppio cieco, controllata con placebo per valutare l’efficacia e la sicurezza di sibeprenlimab somministrato per via sottocutanea in soggetti con nefropatia da immunoglobulina A
- 18-month, open-label, single-arm safety extension study of an age and bodyweightadjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children and young adults (1 to 18 years) with chronic kidney disease and proteinuria
- A multicenter, randomized, double-blind, parallel group, placebo-controlled study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of BI 764198 administered orally once daily for 12 weeks in patients with focal segmental glomeruloscle
- A Phase 3, Randomized, Double-blinded, Placebo-controlled, multicenter study to evaluate the efficacy and safety of Pegcetacoplan in patients with primary C3 glomerulopathy or Immuno-Complex Membranoproliferative Glomerulonephritis
- A PHASE III, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH ISN/RPS 2003 CLASS III OR IV LUPUS NEPHRITIS EUDRACT
- Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALIANT)
- 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age- & body weight-adjusted oral finerenone regimen, in addition to an ACEI/ARB, for the treatment of child. with chronic kidney dis.
- Obinutuzumab in Primary MN (ORION)
- MONET STUDY
- A 9-year, Multicentre, Non-interventional, Post-authorisation Safety Study for Patients Prescribed JINARC® for Autosomal Dominant Polycystic Kidney Disease
- Phase 3 study to evaluate the efficacy and safety of LNP023 on proteinuria and renal function decline in primary IgA nephropathy patients
- Phase 3 study to evaluate the efficacy and safety of LNP023 on proteinuria and renal function decline in primary IgA nephropathy patients
- Rescue Therapy With the Human Anti-CD38 Antibody MOR202 (Felzartamab) in Patients With Membranous Nephropathy Who Failed Anti-CD20 Target Therapy (MONET)
- A PHASE III, RANDOMIZED, OPEN-LABEL ACTIVE COMPARATOR-CONTROLLED MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH PRIMARY MEMBRANOUS NEPHROPATHY
- Phase 2, double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of ravulizumab in adult participants with proliferative lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN)
- Phase 2, double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of ravulizumab in adult participants with proliferative lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN)
- Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN (NOBLE)
- A Phase 3, Randomized, Double-blind, Placebocontrolled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study)
- Rituximab from the first episode of Minimal Change Nephrotic Syndrome for preventing relapse risk in adult patients: a multicenter randomized controlled trial (RIFIREINS)
- A randomized, multicenter, double-blind, parallel, active-control study of the effects of Sparsentan, a dual endothelin receptor and angiotensin receptor blocker, on renal outcomes in patients with primary focal segmental glomerulosclerosis
- Treatment of IGA nEphropathy according to Renal lesions (TIGER)
- A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL-GROUP, ACTIVE-CONTROL STUDY OF THE EFFICACY AND SAFETY OF SPARSENTAN FOR THE TREATMENT OF IMMUNOGLOBULIN A NEPHROPATHY- 021IGAN17001
- OL Extension Study of LNP023 in C3G
- A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, ACTIVECONTROL STUDY OF THE EFFECTS OF SPARSENTAN, A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, ON RENAL OUTCOMES IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
- Vessel wall MRI and Hystology in Polycystic Renal patients aneurysms (VAMPIRE)
- Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy
- AN EXTENDED ACCESS PROGRAM TO ASSESS LONG TERM SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH CHRONIC KIDNEY DISEASE (EAGLE)
- DUPLEX
- PROTECT
- A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Obinutuzumab in Patients With ISN/RPS 2003 Class III or IV Lupus Nephritis
- PROTOCOL RET-D-001: EFFICACY AND SAFETY OF SPARSENTAN(RE-021), A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, IN PATIENTS WITHFOCALSEGMENTAL GLOMERULOSCLEROSIS (FSGS): A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL, DOSE-ESCALATION STUDY
- Genetic, genomic, and biomarker studies of Henoch-Schönlein purpura and IgA nephropathy in kids
Tubulopathies and metabolic disorders
Thrombotic microangiopathies
Structural Kidney Disorders
- 18-month, open-label, single-arm safety extension study of an age and bodyweightadjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children and young adults (1 to 18 years) with chronic kidney disease and proteinuria
- 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age- & body weight-adjusted oral finerenone regimen, in addition to an ACEI/ARB, for the treatment of child. with chronic kidney dis.
- A PHASE 3 TRIAL OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH AUTOSOMAL DOMINANTPOLYCYSTIC KIDNEY DISEASE
- Metformin versus Tolvaptan in adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD): a phase 3a, independent, multi-centre, 2 parallel arms randomized controlled trial
- A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients
CKD and Dialysis in Children
Pediatric Kidney Transplantation
- 18-month, open-label, single-arm safety extension study of an age and bodyweightadjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children and young adults (1 to 18 years) with chronic kidney disease and proteinuria
- A Phase II, randomised, open-label, multicentre study to assess the reactogenicity, safety and immunogenicity of GSK’s PED-HZ/su in paediatric renal transplant recipients (GSK , UK)
- A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant
- A reactogenicity, safety and immunogenicity study of GSK’s paediatric Herpes Zoster subunit candidate vaccine (PED-HZ/su) GSK143713A in immunocompromised paediatric renal transplant recipients.
- Zoster-047 (200075), A Phase II, randomised, open-label, multicentre study to assess the reactogenicity, safety and immunogenicity of GSK’s PED-HZ/su in paediatric renal transplant recipients (GSK , UK)
Cohort Studies and Registries
Glomerulopathies
Tubulopathies and metabolic disorders
Thrombotic microangiopathies
Structural Kidney Disorders
CKD and Dialysis in Children
Pediatric Kidney Transplantation
Translational Research Projects
Glomerulopathies
Tubulopathies and metabolic disorders
Thrombotic microangiopathies
Structural Kidney Disorders
CKD and Dialysis in Children
Pediatric Kidney Transplantation
